Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 01, 2024 08:00 ET | Source: Ardelyx, Inc.

Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the National Kidney Foundation 2024 Spring Clinical Meetings

WALTHAM, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
April 18, 2024 08:00 ET | Source: Ardelyx, Inc.

Ardelyx to Report First Quarter 2024 Financial Results on May 2, 2024

WALTHAM, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
April 12, 2024 08:00 ET | Source: Praxis Precision Medicines, Inc.

Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting

BOSTON, April 12, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...
April 03, 2024 07:30 ET | Source: Mereo BioPharma Group plc

Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

LONDON, April 03, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced...
March 28, 2024 16:05 ET | Source: Ardelyx, Inc.

Ardelyx, Inc. Reports Employment Inducement Grants

WALTHAM, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
March 28, 2024 11:03 ET | Source: Knight Therapeutics

Knight Therapeutics Inc. ranks on The Globe and Mail’s fifth-annual Women Lead Here benchmark of executive gender diversity

MONTREAL, March 28, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”) is pleased to announce it will be recognized on The Globe and Mail’s 2024 Report on...
March 28, 2024 11:03 ET | Source: Thérapeutique Knight inc.

Thérapeutique Knight inc. se mérite une place à la cinquième édition du classement Women Lead Here du Globe and Mail sur la diversité des femmes cadres

MONTRÉAL, 28 mars 2024 (GLOBE NEWSWIRE) -- Thérapeutique Knight inc. (TSX : GUD) (« Knight » ou « la Société ») a le plaisir d’annoncer sa nomination à la cinquième liste annuelle Women Lead...
March 27, 2024 16:01 ET | Source: Mereo BioPharma Group plc

Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update

Phase 2/3 Orbit Study and Phase 3 Cosmic Study of setrusumab in Osteogenesis Imperfecta expected to complete enrollment around the end of first quarter and in the first half of 2024, respectively ...
March 25, 2024 08:00 ET | Source: Ardelyx, Inc.

Ardelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive Vice President, Corporate Development and Strategy

WALTHAM, Mass., March 25, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
March 21, 2024 06:00 ET | Source: Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 Financial Results and Provides Business Update

~ Achieved PEDMARK® Full-Year 2023 Net Product Sales of $21.3 Million, Including $9.7 Million in Net Product Sales in the Fourth Quarter of 2023 ~ ~ Entered Into Exclusive Licensing Agreement to...